Chemotherapy Response Monitoring With 18F-choline PET/CT in Hormone Refractory Prostate Cancer

Status: Completed
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1/Phase 2

The purpose of this study is to determine whether imaging with 18F-choline PET/CT can provide information that may help guide subsequent investigational or clinical treatments for patients with advanced (hormone-refractory) metastatic prostate cancer.

Participation Requirements
Sex: Male
Minimum Age: 18
Healthy Volunteers: No

• Provision of written informed consent.

• Men, over 18 years of age, with histologically-confirmed diagnosis of prostate cancer

• History of treatment by complete androgen blockade for greater than 3 months prior to enrollment

• Progressive disease evidenced by 2 consecutive rises in PSA measured at least 1 week apart, with the absolute value of the latest PSA > 5.0 ng/ml.

• A rise in PSA following anti-androgen drug withdrawal, above the last PSA value before withdrawal.

• Patient has agreed to treatment for hormone-refractory (ie. castrate-resistant) prostate cancer under supervision of a medical oncologist, urologist, radiation oncologist or nuclear medicine physician. Treatments indicated for HRPC are docetaxel-, cabazitaxel-, or mitoxantrone-based chemotherapy, abiraterone, radium-223, enzalutamide, or sipulecuil-T.

United States
The Queen's Medical Center
Time Frame
Start Date: June 2009
Completion Date: June 2016
Target number of participants: 25
Experimental: Received 18F-fluorocholine PET/CT
IV fluorine-18 labeled methylcholine before PET/CT
Related Therapeutic Areas
Collaborators: National Institutes of Health (NIH), National Cancer Institute (NCI)
Leads: Queen's Medical Center

This content was sourced from

Similar Clinical Trials